Published in Aliment Pharmacol Ther on December 23, 2015
Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol (2017) 1.38
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol (2017) 0.77
Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: A randomized trial. Saudi J Gastroenterol (2016) 0.77
A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. Medicine (Baltimore) (2016) 0.76
Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One (2017) 0.75
Evaluation of antimicrobial susceptibility and integron carriage in Helicobacter pylori isolates from patients. Gastroenterol Hepatol Bed Bench (2016) 0.75
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. Digestion (2016) 0.75
Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. Antimicrob Agents Chemother (2017) 0.75
Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol (2017) 0.75
Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep (2016) 0.75
Comparative Evaluation of RUT, PCR and ELISA Tests for Detection of Infection with Cytotoxigenic H. pylori. Adv Pharm Bull (2016) 0.75
Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial. PLoS One (2017) 0.75
Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution? Pharmacogn Rev (2017) 0.75
Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci (2017) 0.75
Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol (2017) 0.75
Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther (2017) 0.75
Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res (2017) 0.75
Role of food in environmental transmission of Helicobacter pylori. Caspian J Intern Med (2017) 0.75
A Novel stool PCR Test for Helicobacter pylori may Predict Clarithromycin Resistance and Patient Eradication at a High Rate. J Clin Microbiol (2017) 0.75
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol Res Pract (2017) 0.75
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 32.58
Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol (1996) 21.37
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Variation in antibiotic use in the European Union. Lancet (2001) 6.02
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis (2014) 5.61
Clinical practice. Helicobacter pylori infection. N Engl J Med (2010) 4.94
Helicobacter pylori persistence: biology and disease. J Clin Invest (2004) 4.75
H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 4.66
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med (2003) 4.65
Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut (2010) 4.43
Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev (2000) 4.03
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther (2007) 3.53
Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol (1998) 3.44
Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev (2007) 3.43
New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol (2008) 2.83
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut (2010) 2.79
Regular review: treatment of Helicobacter pylori infection. BMJ (2000) 2.73
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol (2013) 2.62
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut (2012) 2.49
Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology (2013) 2.49
Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis (2010) 2.40
Guidelines for the management of dyspepsia. Am J Gastroenterol (2005) 2.39
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol (2011) 2.35
Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 2.25
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther (2012) 2.23
Seroprevalence of Helicobacter pylori in South Korea. Helicobacter (2007) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother (2003) 2.12
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2001) 2.10
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
High Helicobacter pylori cure rate with sitafloxacin-based triple therapy. Aliment Pharmacol Ther (2015) 2.01
Susceptibility of Helicobacter pylori to metronidazole. Am J Gastroenterol (2003) 1.98
Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother (1995) 1.94
Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology (2015) 1.85
Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J Infect Dis (2012) 1.84
Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther (2001) 1.81
Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol (2010) 1.80
Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis (2011) 1.80
Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother (1999) 1.80
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ (2013) 1.74
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother (1999) 1.73
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum (2012) 1.73
Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol (1999) 1.72
Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol (2009) 1.71
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother (2001) 1.68
Eradication therapy for Helicobacter pylori. Gastroenterology (2007) 1.67
Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med (2001) 1.66
Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis (2004) 1.63
Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol (2004) 1.63
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother (2001) 1.60
A new look at anti-Helicobacter pylori therapy. World J Gastroenterol (2011) 1.59
Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.55
Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother (2000) 1.54
Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. J Pediatr Gastroenterol Nutr (2014) 1.51
Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology (2012) 1.47
Kyoto global consensus report on Helicobacter pylori gastritis. Gut (2015) 1.47
PNA for rapid microbiology. J Microbiol Methods (2002) 1.46
Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol (2007) 1.45
Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol (2001) 1.44
Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med (2002) 1.43
Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Int J Cancer (1997) 1.38
Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol (2009) 1.37
Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol (2010) 1.36
How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol (2013) 1.34
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter (1999) 1.33
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther (2000) 1.33
Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol (2013) 1.31
Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol (2003) 1.29
Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter (2009) 1.29
Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter (2006) 1.28
Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol (2000) 1.27
Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter (2010) 1.27
Characteristics of gastric cancer in Asia. World J Gastroenterol (2014) 1.26
The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter (2010) 1.26
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut (2000) 1.24
Treatment after failure: the problem of "non-responders". Gut (1999) 1.22
Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther (2010) 1.22
16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.21
Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time. Antimicrob Agents Chemother (1997) 1.21
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2011) 1.21
Epidemiology of Helicobacter pylori infection. Helicobacter (2008) 1.19
Transmission pathway of Helicobacter pylori: does food play a role in rural and urban areas? Int J Food Microbiol (2010) 1.19
Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother (2000) 1.18
Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol (2002) 1.17
Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1996) 1.16
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother (2005) 1.16
Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol (2006) 1.15
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther (2002) 1.14
Helicobacter pylori: a poor man's gut pathogen? Gut Pathog (2010) 1.14
Quadruplex real-time PCR assay using allele-specific scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J Clin Microbiol (2008) 1.14
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter (2007) 1.13
Rapid and accurate determination of genotypic clarithromycin resistance in cultured Helicobacter pylori by fluorescent in situ hybridization. J Clin Microbiol (2001) 1.13
Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol (2011) 1.13
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Authors' reply. Aliment Pharmacol Ther (2016) 0.75